What is Ozempic and why are Australians searching for it?
Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist originally developed to manage blood glucose levels in adults with type 2 diabetes. Its notable side effect, significant appetite suppression and weight reduction, sparked widespread interest across social media and mainstream news, making it one of the most searched pharmaceutical topics in Australia throughout 2024 and 2025.
By 2026, demand has only intensified. According to the Australian Bureau of Statistics, approximately 67% of Australian adults are classified as overweight or obese, fuelling enormous interest in medical weight management solutions. Weight loss clinics across Sydney, Melbourne, Brisbane and Perth now regularly field enquiries about Ozempic, Wegovy (a higher-dose semaglutide product for obesity), and Mounjaro (tirzepatide, a newer dual-agonist).
Understanding the difference between PBS-subsidised access and private prescriptions is critical before you book an appointment or hand over your credit card. The cost difference is often $4,000–$5,000 per year.
How the PBS listing for Ozempic actually works
Ozempic is listed on the PBS under Section 85 (General Schedule) for a specific, restricted indication. The Therapeutic Goods Administration (TGA) approved semaglutide for type 2 diabetes management, and the PBS subsidy follows that approval, not the growing off-label demand for obesity treatment.
To receive a PBS-subsidised prescription, your prescribing doctor must confirm that you have a confirmed diagnosis of type 2 diabetes mellitus, your HbA1c is inadequately controlled despite existing therapy, and the prescription aligns with the approved Authority Required (Streamlined) criteria.
This means a person who is obese but does not have type 2 diabetes can’t access Ozempic via the PBS, even if their GP believes it would benefit them clinically. The subsidy is tightly gatekept, and pharmacists are required to verify Authority codes before dispensing at the subsidised price. For the exact eligibility logic, our PBS Authority decision tree walks you through the criteria in five questions.
What you’ll pay: PBS price vs private price in 2026
Under the PBS in 2026, eligible concession cardholders pay around $7.70 per script, while general patients pay approximately $31.60 per script (subject to the annual Safety Net thresholds). Without PBS eligibility, you face the full private market price.
| Medication | PBS subsidised? | Private cost/month | Typical indication |
|---|---|---|---|
| Ozempic (semaglutide 0.5–1mg) | Yes, T2D only | $380–$450 | Type 2 diabetes; off-label weight loss |
| Wegovy (semaglutide 2.4mg) | No | $420–$530 | Chronic weight management (BMI ≥30 or ≥27 with comorbidity) |
| Saxenda (liraglutide 3mg) | No | $340–$420 | Chronic weight management (daily injection) |
| Mounjaro (tirzepatide) | No (PBS app pending) | $450–$580 | Type 2 diabetes; off-label weight loss |
Prices are indicative private clinic and pharmacy rates sourced from major Australian weight loss clinics as of early 2026. Always confirm current pricing with your provider. Compare your real cost in our GLP-1 switch cost calculator.
Who qualifies for the PBS subsidy, the eligibility criteria explained
If you’re hoping the PBS will cover your Ozempic costs, here is the precise eligibility pathway in 2026:
Step 1, Confirmed type 2 diabetes diagnosis
Your GP or endocrinologist must have formally diagnosed you with type 2 diabetes mellitus. Pre-diabetes, insulin resistance, or polycystic ovary syndrome (PCOS) alone don’t qualify.
Step 2, Inadequate glycaemic control on existing therapy
You must demonstrate that your blood sugar levels are not adequately managed despite being on other approved therapies (typically metformin, or metformin plus a sulfonylurea or DPP-4 inhibitor) at optimal doses.
Step 3, HbA1c threshold
Most PBS Authority criteria for GLP-1 agonists require an HbA1c above 7% (≥53 mmol/mol), with some indications requiring 7.5% (≥58 mmol/mol). Your doctor documents this in the Authority application.
Step 4, Authority Streamlined code on the prescription
Your prescribing doctor enters the relevant Authority Streamlined code directly on the script. No phone call to Services Australia required for straightforward cases. Pharmacists verify the code before dispensing at the subsidised price.
Step 5, Ongoing clinical review
PBS subsidised supply is subject to periodic clinical review. If your HbA1c improves significantly, your prescriber reassesses whether continued Authority approval is warranted. Most patients on PBS Ozempic stay on it long-term once stabilised.
If you don’t tick every box, your prescription will be written privately and you’ll pay accordingly. To check your specific eligibility before booking a GP appointment, use our interactive PBS Authority checker.
Can you access Ozempic for weight loss without a diabetes diagnosis?
Yes, but not through the PBS. Australians who want semaglutide purely for weight management have two realistic pathways in 2026:
1. Private Ozempic prescription (off-label). A registered Australian GP or specialist can prescribe Ozempic off-label for obesity. You pay the full private price (typically $380–$450/month for medication alone, plus consult fees). Some weight loss clinics bundle the consultation, monitoring, and prescription into a monthly programme fee of $290–$450 all-in, often cheaper than retail pharmacy.
2. Wegovy or Mounjaro prescription. Wegovy is TGA-approved for chronic weight management in adults with a BMI ≥30, or ≥27 with at least one weight-related comorbidity. Mounjaro is approved for T2D but increasingly used off-label for weight loss. Neither is PBS-listed, so you’ll pay privately, but they are the more clinically-appropriate options for weight loss compared to off-label Ozempic. Our Wegovy cost guide and Mounjaro cost guide have full pricing breakdowns.
The clinical evidence for semaglutide in weight loss is strong. A landmark 2021 STEP trial published in the New England Journal of Medicine found that participants using semaglutide 2.4mg lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% in the placebo group, a finding that has shaped Australian clinical practice and is the basis for Wegovy's TGA approval.
How to find a reputable clinic and avoid overpaying
With demand for GLP-1 medications at a record high, a wave of telehealth and weight loss clinics has entered the market. Quality varies enormously. Here’s what to look for:
- TGA-registered medications only. Avoid any clinic offering compounded semaglutide that hasn’t been TGA-assessed.
- AHPRA-registered prescribers. Your prescription should come from a GP or specialist registered with AHPRA, not a nurse practitioner operating outside their scope.
- Transparent pricing. Reputable clinics publish their consultation fees, medication costs, and ongoing programme fees upfront. See our methodology for how we assess clinics.
- Baseline monitoring included. Safe GLP-1 prescribing involves baseline blood work, regular HbA1c or weight tracking, and cardiovascular risk review, not just an online questionnaire.
- No "guaranteed results" promises. Any clinic guaranteeing specific weight loss outcomes is operating outside Australian Consumer Law guidelines and the AHPRA advertising code.
Browse our independent directory of verified Australian weight loss clinics, filterable by city, services and bariatric surgeon status.
What changes could affect PBS access in the future?
The Pharmaceutical Benefits Advisory Committee (PBAC) regularly reviews listings. As of early 2026, there is active advocacy from obesity medicine specialists for PBS listing of Wegovy or semaglutide for obesity without a diabetes requirement. The PBAC has previously rejected applications citing budget impact concerns, Australia's PBS budget is significant, and broader access to GLP-1s could cost billions annually.
According to the Australian Institute of Health and Welfare (AIHW), obesity-related conditions cost the Australian healthcare system an estimated $11.8 billion per year, a figure proponents use to argue that subsidised access to effective medications would reduce downstream costs. Watch for the PBAC's quarterly review cycle for updates.
Related coverage
- Is Wegovy covered by PBS in Australia?sibling question, different answer
- Is Mounjaro covered by PBS in Australia?tirzepatide subsidy status
- How Ozempic is prescribed off-labellegitimate pathways
- GLP-1 medications in Australia 2026, full cost comparison
- GLP-1 cost hubdrug-by-drug pricing